本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Intellia Therapeutics Inc

16.11
+3.7029.81%
盤前15.66-0.4500-2.79%06:49 EDT
成交量:1,650.42萬
成交額:2.49億
市值:17.29億
市盈率:-3.44
高:16.38
開:13.14
低:13.00
收:12.41
52周最高:23.68
52周最低:5.90
股本:1.07億
流通股本:1.02億
量比:3.09
換手率:16.18%
股息:- -
股息率:- -
每股收益(TTM):-4.6831
每股收益(LYR):-5.2506
淨資產收益率:-56.95%
總資產收益率:-30.62%
市淨率:2.42
市盈率(LYR):-3.07

資料載入中...

公司資料

公司名字:
Intellia Therapeutics Inc
交易所:
NASDAQ
成立時間:
2014
員工人數:
403
公司地址:
40 Erie Street,Suite 130,Cambridge,Massachusetts,United States
郵編:
02139
電話:
傳真:
- -
簡介:
Intellia Therapeutics, Inc.於2014年5月在特拉華州註冊成立。該公司是一家領先的基因編輯公司,專註於利用最近開發的被稱為CRISPR/ Cas9的系統生物工具進行的獨特的、潛在治癒療法的發展。公司認為CRISPR/ Cas9技術具有通過單一療程永久編輯疾病相關的基因在人體內進行改造藥物的潛力。該公司打算利用其領先的科學專業知識、臨床開發經驗和知識產權地位解鎖CRISPR/ Cas9基因編輯廣泛的治療應用,發展有潛能的新一代治療產品。

董事

名稱
職位
Frank Verwiel
Chairman of the Board
John M. Leonard
Director, President and Chief Executive Officer
Brian Goff
Independent Director
Fred Cohen
Independent Director
Georgia Keresty
Independent Director
Jesse Goodman
Independent Director
Muna Bhanji
Independent Director
William Chase
Independent Director

股東

名稱
職位
John M. Leonard
Director, President and Chief Executive Officer
Edward J. Dulac, III
Treasurer, Executive Vice President and Chief Financial Officer
Birgit Schultes
Executive Vice President and Chief Scientific Officer
Eliana Clark
Executive Vice President and Chief Technology Officer
James Basta
Executive Vice President, General Counsel and Corporate Secretary
Michael P. Dube
Vice President and Chief Accounting Officer